Drug Trial Radar · NCT07822334
A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Oct 28, 2026
Primary completion
Oct 11, 2028
Study completion Jun 20, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple doses of RO7830698 in healthy participants and participants with chronic obstructive pulmonary disease (COPD).
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Healthy Participants
Interventions
RO7830698Drug
Participants will receive RO7830698 as per the schedule described in the protocol.
PlaceboDrug
Participants will receive placebo as per the schedule described in the protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence and Severity of Adverse Events (AEs)Time frame: Up to approximately 50 weeks
- Part 2: Incidence and Severity of AEsTime frame: Up to approximately 44 weeks
- Part 1: Incidence of Dose-limiting Adverse Events (DLAEs)Time frame: Up to approximately 50 weeks
- Part 2: Incidence of DLAEsTime frame: Up to approximately 44 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medicines Evaluation Unit
Wythenshawe, Greater Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.